Jacob Asset Management of New York’s Aerie Pharmaceuticals AERI Stock Holding History

Jacob Asset Management of New York’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-210,143	Closed	-$1.58M	–	69
2022 Q2	$1.58M	Sell	210,143 -36,420	-15%	-$257K	1.59%	25
2022 Q1	$2.24M	Buy	246,563 +1,780	+0.7%	+$13.7K	1.37%	27
2021 Q4	$1.72M	Buy	244,783 +51,517	+27%	+$539K	0.77%	37
2021 Q3	$2.2M	Buy	193,266 +64,166	+50%	+$938K	0.8%	35
2021 Q2	$2.07M	Buy	129,100 +46,000	+55%	+$789K	0.68%	39
2021 Q1	$1.49M	Buy	83,100 +18,000	+28%	+$311K	0.58%	48
2020 Q4	$880K	Buy	+65,100	New	+$787K	0.67%	34

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacob Asset Management of New York's AERI Position: Q3 2022 in Review

Jacob Asset Management of New York sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 210,143 shares — an estimated $1.58M sold.

Jacob Asset Management of New York first reported a position in AERI in Q4 2020 and held it in 7 quarters. The position peaked at $2.24M in Q1 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

Jacob Asset Management of New York reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Jacob Asset Management of New York sold 210,143 Aerie Pharmaceuticals shares in Q3 2022, an estimated $1.58M.
Jacob Asset Management of New York first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Jacob Asset Management of New York's Aerie Pharmaceuticals position peaked at $2.24M in Q1 2022.
156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Jacob Asset Management of New York's 13F filing for Q3 2022, filed 10 Nov 2022.